Physician profile
Michael H Vu
NPI 1134160344
$3,001.93
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,169 · 2020: $25.65 · 2021: $760 · 2022: $29.93 · 2023: $17.75.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $17.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $17.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $397.03 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $308.09 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $298.56 | 2019-2021 | |
| Amarin Pharma, INC. | $239.01 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $200.38 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $171.14 | 2019-2021 | |
| Pfizer INC. | $158.22 | 2019 | |
| Janssen Pharmaceuticals, INC | $145.64 | 2019-2022 | |
| Lilly USA, LLC | $132.18 | 2019 | |
| Amgen INC. | $118.90 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $113.40 | 2019 | |
| Astellas Pharma US INC | $94.99 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $86.01 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.74 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $68.19 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $45.90 | 2019 | |
| Aytu Biopharma, INC. | $41.08 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $40.19 | 2021 | |
| Daiichi Sankyo INC. | $35.30 | 2021 | |
| Abbott Laboratories | $30.98 | 2019 | |
| Fisher & Paykel Healthcare INC | $20.11 | 2021 | |
| Opko Pharmaceuticals, LLC | $19.94 | 2019 | |
| Antares Pharma, INC. | $17.77 | 2019 | |
| Medtronic, INC. | $17.75 | 2023 | Intellis Adaptivestim |
| Mylan Specialty L.P. | $15.30 | 2021 | |
| Glaxosmithkline, LLC. | $14.09 | 2019 | |
| Shire North American Group INC | $13.99 | 2019 | |
| Avanir Pharmaceuticals, INC. | $13.46 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.00 | 2021 | |
| Horizon Therapeutics Plc | $12.97 | 2021 | |
| Mindray Ds USA, INC. | $12.31 | 2021 | |
| Circassia INC. | $12.05 | 2019 | |
| Allergan, INC. | $11.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Vu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.